Global Gene Expression Profiling Reveals SPINK1 as a Potential Hepatocellular Carcinoma Marker

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Marshall, Aileen ^a,b   Lukk, Margus ^a   Kutter, Claudia ^a   Davies, Susan ^b   Alexander, Graeme ^b   Odom, Duncan T ^a,c  

^a CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR KAZAL TYPE 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERINE PROTEINASE INHIBITOR KAZAL TYPE 1 GENE; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; GENE EXPRESSION PROFILING; HEMOCHROMATOSIS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84875064643     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059459     Document Type: Article

References (68)

1. World Heath Organisation Website, GLOBOCAN 2008 (IARC) Section of Cancer information; http://globocan.iarc.fr/factsheets/cancers/liver.asp accessed 1st February 2013.
2. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-76.
3. Cancer Research UK website, http://info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/#Trends accessed 1st February 2013.
4. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, et al. (2009) Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 50: 80-88.
5. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, et al. (2010) Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 28: 2437-2444.
6. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, et al. (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 136: 138-148.
7. Hsing AW, McLaughlin JK, Olsen JH, Mellemkjar L, Wacholder S, et al. (1995) Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 60: 160-162.
8. Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, et al. (2003) Cancer risk in patients with hereditary haemochromatosis and in their first-degree relatives. Gastroenterology 125: 1733-1741.
9. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, et al. (2001) Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 33: 647-651.
10. Stickel F, Hellerbrand C, (2010) Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 59: 1303-7.
11. El-Serag HB, Mason AC, (2000) Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160: 3227-3230.
12. Caballeria L, Pares A, Castells A, Gines A, Bru C, et al. (2001) Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 96: 1160-1163.
13. Cavazza A, Caballería L, Floreani A, Farinati F, Bruguera M, et al. (2009) Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 50: 1162-8.
14. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, et al. (2008) Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 48: 863-870.
15. Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, et al. (2009) Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol 15: 578-82.
16. Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C, (2011) Development of hepatocellular carcinoma in autoimmune hepatitis patients: a case series. Dig Dis Sci 56: 578-85.
17. Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-2. Full guidance available at the American Association for the Study of Liver Diseases website, http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010.pdf Accessed 1st February 2013.
18. International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic Diagnosis of Early Hepatocellular Carcinoma: A Report of the International Consensus Group for Hepatocellular Neoplasia Hepatology. 49: 658-64.
19. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE, (2012) Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 55: 476-82.
20. Flecken T, Spangenberg HC, Thimme R, (2012) Immunobiology of hepatocellular carcinoma Langenbecks Arch Surg. 397: 673-80.
21. Yang JD, Nakamura I, Roberts LR, (2011) The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 21: 35-43.
22. Kazal LA, Spicer DS, Brahinsky RA, (1948) Isolation of a crystalline trypsin inhibitor-anticoagulant protein from pancreas. J Am Chem Soc. 70(9): 3034-40.
23. Stenman UH, Huhtala ML, Koistinen R, Seppälä M, (1982) Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer. 30(1): 53-7.
24. Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH, (1982) Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem. 257(22): 13713-6.
25. Paju A, Stenman UH, (2006) Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci. 43: 103-42.
26. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334: 693-9.
27. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, et al. (2011) Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140: 1501-12.
28. Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, Kennemer MI, et al. (2012) The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 22: 593-601.
29. Levrero M, (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene. 25: 3834-47.
30. Kew MC, (2011) Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 26Suppl 1: 144-52.
31. Abu El Makarem MA, Abdel-Aleem A, Ali A, Saber R, Shatat M, et al. (2011) Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma. Ann Hepatol 10: 296-305.
32. El-Din Bessa SS, Elwan NM, Suliman GA, El-Shourbagy SH, (2010) Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res 41: 541-7.
33. Kim J, Ki SS, Lee SD, Han CJ, Kim YC, et al. (2006) Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 101: 2051-9.
34. Qiao SS, Cui ZQ, Gong L, Han H, Chen PC, et al. (2011) Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 58: 1718-24.
35. Ozkan H, Erdal H, Koçak E, Tutkak H, Karaeren Z, et al. (2011) Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal 25: 350-3.
36. Yasuda E, Kumada T, Toyoda H, Kaneoka Y, Maeda A, et al. (2010) Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 40: 477-85.
37. Ohmachi Y, Murata A, Matsuura N, Yasuda T, Yasuda T, et al. (1993) Specific expression of the pancreatic-secretory-trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma. Int J Cancer 55: 728-34.
38. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, et al. (2007) Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 43: 736-44.
39. Lamontagne J, Pinkerton M, Block TM, Lu X, (2010) Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis. J Virol 84(2): 907-17.
40. Soon WW, Miller LD, Black MA, Dalmasso C, Chan XB, et al. (2011) Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med 3: 451-64.
41. Paju A, Hotakainen K, Cao Y, Laurila T, Gadaleanu V, et al. (2007) Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol. 52(6): 1670-9.
42. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, et al. (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 13(6): 519-28.
43. Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, et al. (2009) Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int. 103(9): 1256-69.
44. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, et al. (2010) Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 16: 2845-51.
45. Solakidi S, Tiniakos DG, Petraki K, Stathopoulos GP, Markaki I, et al. (2003) Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas. Histol Histopathol. 18(4): 1181-8.
46. Gaber A, Nodin B, Hotakainen K, Nilsson E, Stenman UH, et al. (2010) Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer. 10: 498.
47. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, et al. (1995) Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy. Anticancer Res. 15: 2731-7.
48. Hedström J, Haglund C, Leinonen J, Nordling S, Stenman UH, (2001) Trypsinogen-1,-2 and tumour-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas. Scand J Clin Lab Invest 61(2): 111-8.
49. Tonouchi A, Ohtsuka M, Ito H, Kimura F, Shimizu H, et al. (2006) Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection. Am J Gastroenterol 101(7): 1601-10.
50. Wiksten JP, Lundin J, Nordling S, Kokkola A, Stenman UH, et al. (2005) High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology. 46(4): 380-8.
51. Paju A, Jacobsen J, Rasmuson T, Stenman UH, Ljungberg B, (2001) Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol 165: 959-62.
52. Lukkonen A, Lintula S, von Boguslawski K, Carpén O, Ljungberg B, et al. (1999) Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer 83: 486-90.
53. Stenman UH, (2011) SPINK1: a new therapeutic target in cancer? Clin Chem. 57: 1474-5.
54. Stenman UH, (2011) Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development. Asian J Androl 13: 628-9.
55. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, et al. (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med. 2011 3(72): 72ra17.
56. Furuse J, (2008) Growth factors as therapeutic targets in HCC. Crit Rev Oncol Hematol 67: 8-15.
57. Alison MR, Nicholson LJ, Lin WR, (2011) Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res. 185: 135-48.
58. Yasuda T, Ogawa M, Murata A, Ohmachi Y, Yasuda T, et al. (1993) Identification of the IL-6-responsive element in an acute-phase-responsive human pancreatic secretory trypsin inhibitor-encoding gene. Gene 131: 275-80.
59. Kelloniemi E, Rintala E, Finne P, Stenman UH, (2003) Finnbladder Group (2003) Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 62: 249-53.
60. Solakidi S, Dessypris A, Stathopoulos GP, Androulakis G, Sekeris CE, (2004) Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies. Clin Biochem 37: 56-60.
61. Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock IF, et al. (2012) Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers. BJU Int. 2012 Feb 7. doi: 10.1111/j.1464-410X.2011.10922.x.
62. Janeiro E, Guimarães J, Stenman UH, Catarino M, Itkonen O, (2012) Validation and comparison of tumor-associated trypsin inhibitor (TATI) immunoassays. Clin Chim Acta 413: 1244-8.
63. Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, et al. (2011) ArrayExpress update-an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res 39: D1002-4.
64. Barrett T, Troup DB, Wilhite SE, Ledoux P, Evangelista C, et al. (2010) NCBI GEO: archive for functional genomics data sets-10 years on. Nucleic Acids Res 39: D1005-10.
65. Gautier L, Cope L, Bolstad BM, Irizarry RA, (2004) affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315.
66. Smyth GK (2005) Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions using R and Bioconductor by Gentleman R, Carey V, Dudoit S, Irizarry R and Huber W. pp397-420.
67. Benjamini Y, Hochberg Y, (2005) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series 57: 289-300.
68. Alexa A, Rahnenfuhrer J (2010) topGO: Enrichment analysis for Gene Ontology. Bioconducter open source software for Bioinformatics website http://www.bioconductor.org/accessed 19th February 2013.